<DOC>
	<DOCNO>NCT00760617</DOCNO>
	<brief_summary>The purpose study evaluate safety immunogenicity GlaxoSmithKline Biologicals ' influenza vaccine GSK2186877A adult 65 year age old . This protocol post deal objective &amp; outcome measure extension phase year 1 . The objective &amp; outcome measure primary phase present separate protocol posting ( NCT number = 00540592 ) .</brief_summary>
	<brief_title>Evaluation Safety Immunogenicity GSK Biologicals ' Influenza Vaccine GSK2186877A Adults 65 Years Older</brief_title>
	<detailed_description />
	<mesh_term>Influenza , Human</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<criteria>Subjects investigator believe comply requirement protocol . A male female age 1841 year â‰¥65 year time vaccination participate 110847 study complete 6 month followup . Written inform consent obtain subject . Fee acute aggravation health status establish clinical evaluation ( medical history medical history direct examination ) enter study . Female subject must nonchildbearing potential . Use investigational nonregistered product ( drug vaccine ) study vaccine ( ) within 30 day prior vaccination , plan use study period . Administration license vaccine within 2 week ( inactivated vaccine ) 4 week ( live vaccine ) prior enrolment study . Planned administration influenza vaccine study vaccine vaccine foreseen study protocol entire study period . Vaccination influenza since January 2008 seasonal influenza vaccine . Chronic administration ( defined 14 day ) immunosuppressant immunemodifying drug within six month prior administration study vaccine . Any confirm suspected immunosuppressive immunodeficient condition , base medical history physical examination . History hypersensivity previous dose influenza vaccine . History allergy reaction likely exacerbate component vaccine ( ) . Acute ( active ) clinically significant pulmonary , cardiovascular , hepatic renal functional abnormality , determine clinical evaluation ( medical history medical history direct physical examination ) preexist laboratory screening test . Acute disease time enrolment . Administration immunoglobulins and/or blood product within three month precede first administration study vaccine plan administration study . Any medical condition IM injection contraindicate . Lactating female , female plan become pregnant planning discontinue contraceptive precaution .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2016</verification_date>
	<keyword>Influenza</keyword>
	<keyword>Elderly</keyword>
</DOC>